130 related articles for article (PubMed ID: 29651918)
1. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
[TBL] [Abstract][Full Text] [Related]
2. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions.
Gonçalves SC; Sanches SM; Bueno CT; Villela de Castro DL; Damascena A; Santos GRC
J Infus Nurs; 2017; 40(6):380-383. PubMed ID: 29112587
[TBL] [Abstract][Full Text] [Related]
4. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Boccia R; Geller RB; Clendeninn N; Ottoboni T
Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
Laird CM; Glode AE; Schwarz K; Lam ET; O'Bryant CL
J Oncol Pharm Pract; 2020 Sep; 26(6):1369-1373. PubMed ID: 31955703
[TBL] [Abstract][Full Text] [Related]
7. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.
Hegerova LT; Leal AD; Grendahl DC; Seisler DK; Sorgatz KM; Anderson KJ; Hilger CR; Loprinzi CL
Support Care Cancer; 2015 Jan; 23(1):55-9. PubMed ID: 24964876
[TBL] [Abstract][Full Text] [Related]
8. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
Leal AD; Kadakia KC; Looker S; Hilger C; Sorgatz K; Anderson K; Jacobson A; Grendahl D; Seisler D; Hobday T; Loprinzi CL
Support Care Cancer; 2014 May; 22(5):1313-7. PubMed ID: 24402411
[TBL] [Abstract][Full Text] [Related]
9. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
10. Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
Pritchett W; Kinsley K
Clin J Oncol Nurs; 2016 Oct; 20(5):555-6. PubMed ID: 27668376
[TBL] [Abstract][Full Text] [Related]
11. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
12. Infusion Site Reactions: Classification in the Setting of Fosaprepitant Administration With Chemotherapy.
Segna AN; Baron RH; Cohen B
Clin J Oncol Nurs; 2020 Dec; 24(6):E79-E84. PubMed ID: 33216065
[TBL] [Abstract][Full Text] [Related]
13. Systemic hypersensitivity to fosaprepitant - A report of two cases.
Baxley A; Lee Z; Medina P
J Oncol Pharm Pract; 2018 Jan; 24(1):76-78. PubMed ID: 27872331
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
[TBL] [Abstract][Full Text] [Related]
15. [Methods of preventing phlebitis induced by infusion of fosaprepitant].
Kohno E; Kanematsu S; Okazaki S; Ogata M; Kanemitsu M; Yamashita H; Syuntou K; Sekita M; Nishioka R; Yoshida H
Gan To Kagaku Ryoho; 2015 Mar; 42(3):323-6. PubMed ID: 25812501
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
[TBL] [Abstract][Full Text] [Related]
18. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of aprepitant and fosaprepitant in pediatric patients.
Saito Y; Kumamoto T; Arima T; Shirakawa N; Ishimaru S; Sonoda T; Nakajima M; Sugiyama M; Arakawa A; Hashimoto H; Makino Y; Ogawa C; Yamaguchi M
Pediatr Int; 2019 Mar; 61(3):235-239. PubMed ID: 30615239
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]